AMGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Amgen Inc's research and development for the three months ended in Dec. 2013 was $1,249 Mil. Its research and development for the trailing twelve months (TTM) ended in Dec. 2013 was $4,083 Mil.
This is the expense the company spent on research and development.
Amgen Inc Research & Development for the trailing twelve months (TTM) ended in Dec. 2013 was 878 (Mar. 2013 ) + 967 (Jun. 2013 ) + 989 (Sep. 2013 ) + 1249 (Dec. 2013 ) = $4,083 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Amgen Inc Annual Data
|Research & Development||2,028||2,314||3,366||3,266||3,030||2,864||2,894||3,167||3,380||4,083|
Amgen Inc Quarterly Data
|Research & Development||761||851||736||826||880||938||878||967||989||1,249|